EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Interpharm Consultancy
Founder
Interpharm Consultancy has been providing advice about the UK generic market and consultancy services to generic manufacturers and distributors
Articles
Biologics at Scale
Biologics including monoclonal antibodies vaccines and advanced cell and gene therapies CGT require an integrated innovation and production ecosystem This ecosystem rests on six pillars Manufacturing Infrastructure Regulatory Environment Talent and Training Innovation Hubs Funding s Investment and PublicPrivate Partnerships In recent years global and AsiaPacific leaders have accelerated efforts...
Research Insights
Phenotype to Genotype: A New and Rapid Approach Using Whole-genome Sequencing
Forward genetic screening is a powerful approach to assign functions to genes and can be used to elucidate the many genes whose functions remain unknown A key step in forward genetic screening is mapping identification
Case Studies
A Dose-Escalation Case Study Of A Second-Generationnon-Ansamycin HSP90 Inhibitor, Onalespib (AT13387), Incombination With Imatinib In Patients With Metastaticgastrointestinal Stromal Tumour
Abstract Gastrointestinal stromal tumours GIST are commonly driven by activating mutations in the KIT or PDGFRA receptor tyrosine kinases Although the initial response rates for newly diagnosed GIST to the tyrosine kinase inhibitorTKI imatinib can be most tumours ultimately become resistant commonly through secondary mutations or through alternative pa
Techno Trends
Breakthrough Therapy Designation to Adcetris for Frontline Advanced Hodgkin Lymphoma
ADCETRIS brentuximab vedotin in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma has been granted breakthrough therapy designation by FDA ADCETRIS is an antibody drug conjugate ADC directed to CD a defining marker of classical Hodgkin lymphoma It is being evaluated globally as the foundation of care f...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
A BITTER PILL: Exploring the Realm of Drug Counterfeiting
Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
From Gene Editing to Network Medicine
Prof. Dr. Hemanth Kumar Manikyam is a researcher in natural products chemistry and systems pharmacology. He is widely known as the father of Intrinsic Network Pharmacology (INP), an integrative framework combining artificial intelligence, biological network analysis, and traditional medicinal knowledge to explore complex therapeutic mechanisms and next-generation precision medicine.
Emerging Technologies in Pharmaceutical Sciences
Abhishek Rungta is the Founder and CEO of INT. (Indus Net Technologies), a full-stack digital transformation company serving 500+ enterprise clients across 45 countries. He writes on enterprise AI adoption, digital transformation, and long-term business building.
Impact Assessment of US Tariff Threat on Indian Healthcare Export
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
press releasesRead more...
Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery
AIdriven protein design is accelerating the discovery of novel protein binders but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions To bridge this gap Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in r...
Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer
Innovent Biologics Inc Innovent HKEX a worldclass biopharmaceutical company that develops manufactures and commercializes highquality medicines for the treatment of oncologic autoimmune cardiovascular and metabolic
LOTTE Biologics Secures Major Commercial Manufacturing Agreement Ahead of Songdo Plant 1 Launch
LOTTE Biologics CoCEOs James Park and Yooyeol Shin today announced a major commercial manufacturing agreement with a global pharmaceutical company marking a significant milestone in the commercialization of its Songdo Bio Campus
Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer
Akeso Inc HK Akeso or the Company announced that the National Medical Products Administration NMPA of China has accepted the supplemental New Drug Application sNDA for ivonescimab in combination with chemotherapy
Biomapas Establishes Us Presence With Acquisition of Alira Health’s Cmc Business
Biomapas a leading integrated life sciences services provider today announced its entry into the US market with the acquisition of the Chemistry Manufacturing and Controls CMC business of Alira Health The Bostonbased team which provides integrated
EventsRead more...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWSRead more...
OBI Pharma and Novartis Partner to Develop Next-Generation ADCs for Cancer Treatment
OBI Pharma has entered into a collaboration and licensing agreement with Novartis to develop nextgeneration antibodydrug conjugates ADCs using novel payloads and OBIs proprietary technology platforms
Merck to Acquire Rapid Micro Biosystems to Strengthen Automation in Pharmaceutical Quality Control
Merck has signed a definitive agreement to acquire Rapid Micro Biosystems a USbased provider of automated microbial qualitycontrol testing solutions for pharmaceutical manufacturing
Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer
Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer
Eppendorf Invests €40 Million in New Manufacturing Facility in Penang, Malaysia
Eppendorf has started construction of a new manufacturing facility at Bandar Cassia Technology Park in Penang Malaysia
Lilly Invests US$3.5 Billion in New Manufacturing Facility for Obesity Medicines in Pennsylvania
Eli Lilly and Company has started construction of a US billion manufacturing facility in Lehigh Valley Pennsylvania as part of its plans to expand medicine production in the United States The new site is one of manufacturing facilities
Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer
Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC


